Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 52.05
(0.97%)
EUR 52.05
(0.97%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 46.63 Million EUR | -9.34% |
| 2022 | 72.16 Million EUR | -1.36% |
| 2021 | 73.16 Million EUR | -1.72% |
| 2020 | 74.44 Million EUR | -12.22% |
| 2019 | 84.8 Million EUR | 147.79% |
| 2018 | 34.22 Million EUR | -20.85% |
| 2017 | 43.23 Million EUR | 27.94% |
| 2016 | 33.79 Million EUR | 19.93% |
| 2015 | 28.17 Million EUR | -22.38% |
| 2014 | 36.3 Million EUR | 17.2% |
| 2013 | 30.97 Million EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 81.77 Million EUR | 24.99% |
| 2024 Q2 | 103.7 Million EUR | 48.16% |
| 2023 FY | 65.42 Million EUR | -9.34% |
| 2023 Q2 | 66.5 Million EUR | -4.05% |
| 2023 Q1 | 69.3 Million EUR | -3.96% |
| 2023 Q3 | 63.65 Million EUR | -4.28% |
| 2023 Q4 | 65.42 Million EUR | 2.78% |
| 2022 Q2 | 73.12 Million EUR | 1.16% |
| 2022 FY | 72.16 Million EUR | -1.36% |
| 2022 Q4 | 72.16 Million EUR | -1.98% |
| 2022 Q3 | 73.62 Million EUR | 0.67% |
| 2022 Q1 | 72.29 Million EUR | -1.19% |
| 2021 Q2 | 72.83 Million EUR | 0.16% |
| 2021 Q1 | 72.71 Million EUR | 1.88% |
| 2021 Q4 | 73.16 Million EUR | 1.77% |
| 2021 Q3 | 71.89 Million EUR | -1.29% |
| 2021 FY | 73.16 Million EUR | -1.72% |
| 2020 Q4 | 71.37 Million EUR | -4.71% |
| 2020 FY | 74.44 Million EUR | -12.22% |
| 2020 Q3 | 74.9 Million EUR | -0.6% |
| 2020 Q2 | 75.35 Million EUR | -1.7% |
| 2020 Q1 | 76.65 Million EUR | -5.76% |
| 2019 Q2 | 45.36 Million EUR | -6.76% |
| 2019 Q4 | 81.34 Million EUR | 99.64% |
| 2019 Q1 | 48.65 Million EUR | 42.16% |
| 2019 FY | 84.8 Million EUR | 147.79% |
| 2019 Q3 | 40.74 Million EUR | -10.18% |
| 2018 Q1 | 40.42 Million EUR | -6.52% |
| 2018 Q3 | 39.51 Million EUR | 2.76% |
| 2018 Q2 | 38.45 Million EUR | -4.85% |
| 2018 FY | 34.22 Million EUR | -20.85% |
| 2018 Q4 | 34.22 Million EUR | -13.4% |
| 2017 Q4 | 43.23 Million EUR | -8.21% |
| 2017 FY | 43.23 Million EUR | 27.94% |
| 2017 Q3 | 47.1 Million EUR | -4.13% |
| 2017 Q2 | 49.13 Million EUR | -4.22% |
| 2017 Q1 | 51.3 Million EUR | 51.8% |
| 2016 FY | 33.79 Million EUR | 19.93% |
| 2016 Q3 | 37.62 Million EUR | -5.27% |
| 2016 Q2 | 39.72 Million EUR | -4.15% |
| 2016 Q1 | 41.44 Million EUR | -3.12% |
| 2016 Q4 | 33.79 Million EUR | -10.19% |
| 2015 Q1 | 35.93 Million EUR | -1.01% |
| 2015 FY | 28.17 Million EUR | -22.38% |
| 2015 Q4 | 42.77 Million EUR | -3.1% |
| 2015 Q3 | 44.14 Million EUR | 26.0% |
| 2015 Q2 | 35.03 Million EUR | -2.51% |
| 2014 Q2 | 25.21 Million EUR | -16.59% |
| 2014 Q1 | 30.22 Million EUR | -2.42% |
| 2014 FY | 36.3 Million EUR | 17.2% |
| 2014 Q4 | 36.3 Million EUR | -2.65% |
| 2014 Q3 | 37.29 Million EUR | 47.91% |
| 2013 Q3 | 31.52 Million EUR | -1.64% |
| 2013 FY | 30.97 Million EUR | 0.0% |
| 2013 Q4 | 30.97 Million EUR | -1.74% |
| 2013 Q1 | 38.08 Million EUR | 0.0% |
| 2013 Q2 | 32.05 Million EUR | -15.84% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Boiron SA | 13.7 Million EUR | -240.352% |
| Vetoquinol SA | 17.62 Million EUR | -164.551% |
| Valneva SE | 208.81 Million EUR | 77.667% |
| AB Science S.A. | 19.1 Million EUR | -144.15% |
| Nanobiotix S.A. | 45.48 Million EUR | -2.533% |
| PHAXIAM Therapeutics S.A. | 10.19 Million EUR | -357.251% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -122623.684% |
| BioSenic S.A. | 28.16 Million EUR | -65.601% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 15.918% |
| Formycon AG | 29.48 Million EUR | -58.16% |